Evecxia Therapeutics Highlights P-I Trial Results of Adjunctive EVX-101 for Depressive Disorders
Shots:
-
The P-I (SAD-MAD), a 2-part single & multiple ascending dose trial of EVX-101 in healthy volunteers with escitalopram. The trial was conducted at Quotient Sciences’ Nottingham, UK facility
-
In part 2 MAD, 5-HTP plasma levels increased with each escalation in carbidopa dose. The PD biomarker data demonstrated target engagement, indicative of brain extracellular serotonin elevation beyond the 1L antidepressant effect
-
AEs were consistent with the serotonergic pharmacology & gastrointestinal events, no serotonin toxicity or other safety signals were seen, and dose titration substantially improved tolerability. The dose range was established for the planned P-II trial in major depressive disorder patients inadequately responding to 1L antidepressant therapy
Ref: Businesswire | Image: Evecxia Therapeutics
Related News:- Evecxia Therapeutics Receives Notice of Allowance from the US PTO Covering EVX‑101
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
